|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:acquisitionYear
|
2019
|
|
gptkbp:category
|
Companies formerly listed on the London Stock Exchange
Companies formerly listed on NASDAQ
Biotechnology companies of the United Kingdom
Defunct pharmaceutical companies of the United Kingdom
|
|
gptkbp:countryOfOrigin
|
gptkb:United_Kingdom
|
|
gptkbp:defunct
|
2019
|
|
gptkbp:founded
|
1986
|
|
gptkbp:founder
|
Harry Stratford
|
|
gptkbp:headquartersLocation
|
gptkb:Dublin,_Ireland
gptkb:Basingstoke,_United_Kingdom
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Shire plc
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Flemming_Ørnskov
gptkb:Susan_Kilsby
|
|
gptkbp:listedOn
|
gptkb:FTSE_100_Index
|
|
gptkbp:mergedInto
|
gptkb:Baxalta
|
|
gptkbp:netIncome
|
$4.27 billion (2017)
|
|
gptkbp:notableProduct
|
gptkb:Cinryze
gptkb:Firazyr
gptkb:Lialda
gptkb:Natpara
gptkb:Vyvanse
Elaprase
Replagal
Adderall XR
Baxalta (acquired company)
Gattex
Intuniv
Xagrid
|
|
gptkbp:numberOfEmployees
|
~5,000 (2017)
|
|
gptkbp:parentCompany
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:products
|
rare disease treatments
gastrointestinal drugs
hematology drugs
neuroscience drugs
|
|
gptkbp:revenue
|
$15.16 billion (2017)
|
|
gptkbp:status
|
defunct
|
|
gptkbp:stockExchange
|
gptkb:London_Stock_Exchange
gptkb:NASDAQ
|
|
gptkbp:tradedOn
|
LSE: SHP
NASDAQ: SHPG
|
|
gptkbp:website
|
www.shire.com
|
|
gptkbp:bfsParent
|
gptkb:Takeda
gptkb:Takeda_(Japan)
|
|
gptkbp:bfsLayer
|
6
|